vs

Side-by-side financial comparison of ETHAN ALLEN INTERIORS INC (ETD) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $135.8M, roughly 1.1× ETHAN ALLEN INTERIORS INC). ETHAN ALLEN INTERIORS INC runs the higher net margin — 4.4% vs -5.5%, a 9.9% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -4.8%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -10.2%).

Ethan Allen Interiors Inc. is an American manufacturer and retailer of home furnishings, incorporated in Delaware with executive offices in Danbury, Connecticut. As of June 30, 2023, the company reported net annual sales of $791.4 million.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

ETD vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.1× larger
TARS
$151.7M
$135.8M
ETD
Growing faster (revenue YoY)
TARS
TARS
+133.2% gap
TARS
128.4%
-4.8%
ETD
Higher net margin
ETD
ETD
9.9% more per $
ETD
4.4%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-10.2%
ETD

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
ETD
ETD
TARS
TARS
Revenue
$135.8M
$151.7M
Net Profit
$5.9M
$-8.4M
Gross Margin
59.4%
Operating Margin
4.8%
-5.3%
Net Margin
4.4%
-5.5%
Revenue YoY
-4.8%
128.4%
Net Profit YoY
-38.2%
63.8%
EPS (diluted)
$0.23
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ETD
ETD
TARS
TARS
Q1 26
$135.8M
Q4 25
$149.9M
$151.7M
Q3 25
$147.0M
$118.7M
Q2 25
$160.4M
$102.7M
Q1 25
$142.7M
$78.3M
Q4 24
$157.3M
$66.4M
Q3 24
$154.3M
$48.1M
Q2 24
$168.6M
$40.8M
Net Profit
ETD
ETD
TARS
TARS
Q1 26
$5.9M
Q4 25
$11.7M
$-8.4M
Q3 25
$10.5M
$-12.6M
Q2 25
$-20.3M
Q1 25
$9.6M
$-25.1M
Q4 24
$15.0M
$-23.1M
Q3 24
$14.7M
$-23.4M
Q2 24
$18.5M
$-33.3M
Gross Margin
ETD
ETD
TARS
TARS
Q1 26
59.4%
Q4 25
60.9%
Q3 25
61.4%
Q2 25
59.9%
Q1 25
61.2%
Q4 24
60.3%
Q3 24
60.8%
Q2 24
60.8%
Operating Margin
ETD
ETD
TARS
TARS
Q1 26
4.8%
Q4 25
9.5%
-5.3%
Q3 25
6.8%
-12.2%
Q2 25
9.5%
-21.6%
Q1 25
7.7%
-33.5%
Q4 24
11.5%
-36.8%
Q3 24
11.4%
-52.3%
Q2 24
13.4%
-81.6%
Net Margin
ETD
ETD
TARS
TARS
Q1 26
4.4%
Q4 25
7.8%
-5.5%
Q3 25
7.1%
-10.6%
Q2 25
-19.8%
Q1 25
6.7%
-32.1%
Q4 24
9.5%
-34.8%
Q3 24
9.5%
-48.7%
Q2 24
11.0%
-81.6%
EPS (diluted)
ETD
ETD
TARS
TARS
Q1 26
$0.23
Q4 25
$0.46
$-0.17
Q3 25
$0.41
$-0.30
Q2 25
$0.48
$-0.48
Q1 25
$0.37
$-0.64
Q4 24
$0.59
$-0.57
Q3 24
$0.57
$-0.61
Q2 24
$0.73
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ETD
ETD
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$66.6M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$473.7M
$343.4M
Total Assets
$723.3M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ETD
ETD
TARS
TARS
Q1 26
$66.6M
Q4 25
$139.3M
$417.3M
Q3 25
$123.6M
$401.8M
Q2 25
$136.1M
$381.1M
Q1 25
$172.9M
$407.9M
Q4 24
$139.1M
$291.4M
Q3 24
$135.9M
$317.0M
Q2 24
$161.0M
$323.6M
Total Debt
ETD
ETD
TARS
TARS
Q1 26
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
ETD
ETD
TARS
TARS
Q1 26
$473.7M
Q4 25
$478.2M
$343.4M
Q3 25
$475.5M
$335.1M
Q2 25
$482.4M
$332.6M
Q1 25
$479.2M
$342.5M
Q4 24
$478.8M
$224.5M
Q3 24
$474.7M
$237.5M
Q2 24
$483.0M
$252.2M
Total Assets
ETD
ETD
TARS
TARS
Q1 26
$723.3M
Q4 25
$714.8M
$562.2M
Q3 25
$737.1M
$534.6M
Q2 25
$737.1M
$495.0M
Q1 25
$738.7M
$500.8M
Q4 24
$732.6M
$377.0M
Q3 24
$737.7M
$376.3M
Q2 24
$744.9M
$376.8M
Debt / Equity
ETD
ETD
TARS
TARS
Q1 26
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ETD
ETD
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ETD
ETD
TARS
TARS
Q1 26
Q4 25
$-1.8M
$19.3M
Q3 25
$16.8M
$18.3M
Q2 25
$24.8M
$-29.4M
Q1 25
$10.2M
$-20.7M
Q4 24
$11.6M
$-22.2M
Q3 24
$15.1M
$-8.7M
Q2 24
$26.2M
$-14.4M
Free Cash Flow
ETD
ETD
TARS
TARS
Q1 26
Q4 25
$-4.7M
$13.0M
Q3 25
$14.4M
$16.3M
Q2 25
$22.9M
$-30.4M
Q1 25
$8.2M
$-21.2M
Q4 24
$7.8M
$-22.3M
Q3 24
$11.5M
$-8.9M
Q2 24
$24.2M
$-15.4M
FCF Margin
ETD
ETD
TARS
TARS
Q1 26
Q4 25
-3.2%
8.6%
Q3 25
9.8%
13.8%
Q2 25
14.3%
-29.6%
Q1 25
5.7%
-27.1%
Q4 24
5.0%
-33.5%
Q3 24
7.4%
-18.6%
Q2 24
14.3%
-37.8%
Capex Intensity
ETD
ETD
TARS
TARS
Q1 26
Q4 25
1.9%
4.2%
Q3 25
1.6%
1.6%
Q2 25
1.2%
1.0%
Q1 25
1.4%
0.8%
Q4 24
2.4%
0.1%
Q3 24
2.3%
0.6%
Q2 24
1.2%
2.5%
Cash Conversion
ETD
ETD
TARS
TARS
Q1 26
Q4 25
-0.16×
Q3 25
1.61×
Q2 25
Q1 25
1.06×
Q4 24
0.77×
Q3 24
1.02×
Q2 24
1.42×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons